

Date: December 3, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

Script Code: 543904

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Outcome of Board Meeting held today i.e. December 3, 2024

The Board of Directors of the Company at its meeting held today i.e. April 2, 2024, has inter-alia, considered and approved the following:

1. the disposal of the Company's partnership interest in Mankind Specialties to Vascare Sciences Private Limited, a Company incorporated under the Companies Act, 1956 for a lumpsum consideration of approximately ₹ 4 Crores.
2. appointment of Mr. Ashish Mittal (ICSI Membership No. A25169) as Company Secretary and Compliance officer of the Company and Key Managerial Personnel and designated as Deputy Company Secretary with effect from December 3, 2024, as recommended by Nomination and Remuneration Committee.
3. the following Key Managerial Personnel of the Company are severally authorized for the purpose of dissemination of material event/information to the Stock Exchanges

S. No	Name and Designation	Contact Details
1	Mr. Ashutosh Dhawan Chief Financial Officer	Mankind Pharma Limited Corporate Office: 262, Okhala Industrial Estate, Phase – III, New Delhi 110020
2	Mr. Ashish Mittal Company Secretary & Compliance Officer	Phone: 011 – 4684 6700 Email ID: investors@mankindpharma.com

The detailed disclosure as required under SEBI Listing Regulations for aforesaid point no 1 and 2 is enclosed as Annexure I and II respectively.

The meeting of Board of Directors of the Company commenced at 03:15 p.m. (IST) and concluded at 06:30 p.m. (IST).

MANKIND PHARMA LIMITED



Mankind

Serving Life

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Ashutosh Dhawan
Chief Financial Officer

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com

Annexure I

Disclosure as per SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	Details
1.	the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Revenue/Income of Mankind Specialties for FY 2023-2024 is Rs. 2.60 crore (0.03% of Rs. 9,264.80 crore being Revenue/Income of the Company). Net-worth of Mankind Specialties as on March 31, 2024, is Rs. 3.26 crore (0.03% of Net Worth of Company). Net worth of Company as on March 31, 2024 is Rs 9,363.09 crore.
2.	date on which the agreement for sale has been entered into;	The Agreement will be executed in due course.
3.	the expected date of completion of sale/disposal;	It is proposed to dispose-off partnership interest with effect from January 2025 subject to customary requirements.
4.	consideration received from such sale/disposal;	The Board of Directors of the Company has approved the disposal of the Company's partnership interest in Mankind Specialties to Vascare Sciences Private Limited, a Company incorporated under the Companies Act, 1956 ("Buyer") for a lumpsum consideration of ₹ 4 Crores (approx) subject to satisfactory due diligence requirements.
5.	brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof;	The Buyer does not belong to the promoter/ promoter group/group companies.
6.	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	The transaction does not fall within related party transactions.
7.	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not Applicable
8.	additionally, in case of a slump sale, indicative disclosures	Not Applicable

MANKIND PHARMA LIMITED



	provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	
--	--	--

MANKIND PHARMA LIMITED

Annexure II

Disclosure as per SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	Details
1.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Mr. Ashish Mittal (ICSI Membership No. A25169) appointed as Company Secretary and Compliance officer of the Company and Key Managerial Personnel and designated as Deputy Company Secretary with effect from December 3, 2024, as recommended by Nomination and Remuneration Committee.
2.	date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	
3.	brief profile (in case of appointment);	Mr. Ashish Mittal, aged 40 years is a qualified Company Secretary and a law graduate having over 15 years of experience in the field of Corporate Governance, compliance management, fund raising activities, IPO etc. He has joined the Company in April 2024 as AGM- Secretarial. Prior to joining Mankind Pharma Limited he was associated with Companies like Hero MotoCorp Limited, MMTC Limited, Jubilant Foodworks Limited and Uflex Limited.
4	disclosure of relationships between directors (in case of appointment of a director).	Not Applicable